The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of oral rucaparib in combination with carboplatin.
L Rhoda Molife
Research Funding - Clovis
Patricia Roxburgh
Research Funding - Clovis
Richard H. Wilson
Consultant or Advisory Role - Clovis
Research Funding - Clovis
Avinash Gupta
Research Funding - Clovis
Mark R. Middleton
Consultant or Advisory Role - Clovis
Research Funding - Clovis
T. R. Jeffry Evans
Consultant or Advisory Role - Clovis
Research Funding - Clovis
Caroline Ogilvie Michie
Research Funding - Clovis
Joaquin Mateo
Research Funding - Clovis
Donna Crawford
Research Funding - Clovis
Martin McKinlay Eatock
Research Funding - Clovis
Wasir Saka
Research Funding - Clovis
Nicola Cresti
Research Funding - Clovis
Yvette Drew
Research Funding - Clovis
Heidi Giordano
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Darrin Despain
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Dayna Simpson
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Andrew R. Allen
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Sarah S. Jaw-Tsai
Employment or Leadership Position - Clovis
Consultant or Advisory Role - Clovis
Stock Ownership - Clovis
Ruth Plummer
Honoraria - Clovis
Research Funding - Clovis